Barry J. Simon sold $1.8M of IBRX
director at ImmunityBio, Inc.. 175,000 shares at an average of $10.19, traded Feb 20, 2026, filed Feb 24, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.8M at market
- 0Share of holdings soldSold 5.7% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -36.1%, 3m -31.4%, 6m -29.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001647994-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | SOpen-market sale Common Stock10b5-1 | -10,000 | $9.25 | $93k | 3,081,604 | Feb 24, 2026 |
| Feb 22, 2026 | MOption exercise Common Stock10b5-1 | +15,243 | $0.00 | $0 | 3,096,847 | Feb 24, 2026 |
| Feb 22, 2026 | FTax withholding Common Stock10b5-1 | -6,026 | $8.70 | $52k | 3,090,821 | Feb 24, 2026 |
| Feb 23, 2026 | SOpen-market sale Common Stock10b5-1 | -165,000 | $10.25 | $1.7M | 2,925,821 | Feb 24, 2026 |
| Feb 22, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -15,243 | $0.00 | $0 | 15,245 | Feb 24, 2026 |
Related signals
Other insiders at ImmunityBio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | ImmunityBio, Inc. | Cheryl Cohen director | $851k 81,056 shares | -45% | |
| 16Weak | ImmunityBio, Inc. | Barry J. Simon director | $269k 25,000 shares | -1% | |
| 40Moderate | ImmunityBio, Inc. | Cheryl Cohen director | $1.2M 131,210 shares | -51% | |
| 40Moderate | ImmunityBio, Inc. | Christobel Selecky director | $1.4M 159,478 shares | -100% | |
| 38Weak | ImmunityBio, Inc. | Christobel Selecky director | $871k 96,722 shares | -101% | |
| 22Weak | ImmunityBio, Inc. | Barry J. Simon director | $197k 25,000 shares | -1% | |
| 6Weak | ImmunityBio, Inc. | Barry J. Simon director | $165k 23,033 shares | -1% | |
| 27Weak | ImmunityBio, Inc. | Barry J. Simon director | $901k 75,000 shares | -3% | |
| 21Weak | ImmunityBio, Inc. | Christobel Selecky director | $250k 25,000 shares | -100% | |
| 28Weak | ImmunityBio, Inc. | Barry J. Simon director | $1.1M 151,967 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.